Regeneron Pharmaceuticals (REGN) Downgraded by BidaskClub to “Sell”

BidaskClub lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a sell rating in a report released on Tuesday morning, BidAskClub reports.

REGN has been the topic of a number of other research reports. TheStreet raised Regeneron Pharmaceuticals from a c+ rating to a b rating in a research note on Thursday, January 17th. Guggenheim raised Regeneron Pharmaceuticals from a neutral rating to a buy rating and set a $461.00 price target on the stock in a research note on Friday, January 4th. Cowen reissued a hold rating and issued a $385.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th. Cantor Fitzgerald reissued a hold rating and issued a $441.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 6th. Finally, Oppenheimer increased their price target on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an outperform rating in a research note on Thursday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of Hold and a consensus target price of $413.76.

NASDAQ:REGN opened at $367.69 on Tuesday. Regeneron Pharmaceuticals has a 52-week low of $281.89 and a 52-week high of $442.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. The firm has a market cap of $41.03 billion, a price-to-earnings ratio of 18.57, a PEG ratio of 1.49 and a beta of 1.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the prior year, the business earned $5.23 EPS. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals will post 19.92 earnings per share for the current year.

In related news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 12.42% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.1% in the 4th quarter. BlackRock Inc. now owns 5,929,225 shares of the biopharmaceutical company’s stock valued at $2,214,564,000 after buying an additional 67,241 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after buying an additional 75,868 shares in the last quarter. Vanguard Group Inc increased its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after purchasing an additional 75,868 shares in the last quarter. FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.6% during the 4th quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after purchasing an additional 330,875 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock worth $402,138,000 after purchasing an additional 78,143 shares in the last quarter. Institutional investors and hedge funds own 66.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Why are percentage decliners important?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit